Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03251989 · ClinicalTrials.gov registry record
Rare CNS Tumors Outcomes &Risk
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 326
- Enrollment target
NCT03251989: Completed study, sponsored by National Cancer Institute (NCI).
NCT03251989 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 326 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03251989 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 326 participants
- Enrollment target
Study Summary
Background: Primary tumors of the brain and spine are those that start in the brain or spine. These tumors are rare, accounting for \<2% of all cancers diagnosed in the United States. Some of these tumors occur in less than 2,000 people per year. Researchers want to study a large group of people with this kind of tumor. They want to learn more about the tumors, including the risk factors related to how they develop in adults. Objective: To collect health and gene data to learn about what changes are associated with a rare CNS Tumors, to eventually screen for these changes or target the genes in treatment. Eligibility: Adult participants \>= 18 years of age who self- identify as being diagnosed with one of 12 rare CNS tumors, including: Atypical teratoid rhabdoid tumor (ATRT); Brainstem and midline gliomas; Choroid plexus tumors; Ependymoma; High grade meningioma; Gliomatosis cerebri; Medulloblastoma; Oligodendroglioma / Anaplastic oligodendroglioma; Pineal region tumors; Pleomorphic xanthroastrocytoma / Anaplastic pleomorphic xanthroastrocytoma; PNET (Supratentorial embryonal tumor); Primary CNS sarcoma / Secondary CNS sarcoma (Gliosarcoma). Design: Participants will be invited to participate through an ad on the CERN Foundation website (ependymoma), information on the Neuro-Oncology Branch website and other identified advocacy and social media sites and direct mailer to those who have already participated in the EO projects. (Registered Trademark) * Interested participants will complete an enrollment form that will be sent to the study coordinator. * The coordinator will then send the participant a consent form and schedule a time for phone consent. * Participants will complete the Rare CNS tumors Outcomes Survey and once completed, the Rare CNS tumors Risk survey. (Registered Trademark) * The questions on the Outcomes Survey will include treatment history, symptoms social and clinical information and it should take about 25-35 minutes. The Risk survey will c
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2017-08-21 |
| Est. Completion | 2025-05-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03251989
The ClinicalTrials.gov registry entry for NCT03251989 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03251989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03251989 about?
NCT03251989 is a clinical study titled "Rare CNS Tumors Outcomes &Risk". Background: Primary tumors of the brain and spine are those that start in the brain or spine. These tumors are rare, accounting for \<2% of all cancers diagnosed in the United States. Some of these tumors occur in less than 2,000 people per year. Researchers want to study a large group of people wi...
What is the current status of trial NCT03251989?
This trial is currently completed. The enrollment target is 326 participants. The study started on 2017-08-21. Estimated completion is 2025-05-06.
Who is sponsoring clinical trial NCT03251989?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.